Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Investors put $93mm into Paratek as part of merger with Transcept

Executive Summary

As part of its reverse merger with public neuroscience firm Transcept Pharmaceuticals Inc., infectious disease-focused Paratek Pharmaceuticals Inc. will receive $93mm from its current stockholders Omega Funds, HBM Healthcare Investments, and Aisling Capital; Transcept shareholders InterWest Ventures and Roumell Asset Management; and new backers The Baupost Group, Abingworth, and other institutional investors. Post-acquisition, Paratek will focus on lead compound omadacycline, a Phase III-ready oral and intravenous antibiotic.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies

UsernamePublicRestriction

Register